about
IL-6 as a druggable target in psoriasis: focus on pustular variants.Lasers and Energy Devices for the Skin: Conventional and Unconventional UseSensors and Biosensors for C-Reactive Protein, Temperature and pH, and Their Applications for Monitoring Wound Healing: A Review.A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.Optimizing acitretin use in patients with plaque psoriasis.Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus.The patient journey: a voyage from diagnosis to hidradenitis suppurativa multidisciplinary unitSecukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world studySecukinumab in the therapy of psoriasis and psoriatic arthritis: a safe choice in clinical practiceEfficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experienceTesting biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approachesEtanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registryThe pharmacological management of patients with comorbid psoriasis and obesityEmerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potentialRisankizumab for the treatment of moderate to severe psoriasis
P50
Q34003280-003A9C49-7EB6-4D54-B489-8C291450FB8AQ36207367-424FE6F0-809D-478C-B1DC-3886CBEDE594Q47276781-13393E9E-416A-453C-BB1F-09605BE6FDDDQ47657450-EF870406-3A51-4B72-B28B-C1F130031DE7Q48133364-5EDC47CD-790E-4F7E-877E-59E08A612C3FQ48304684-AFA04033-1E06-4FE1-B3CE-94444413B2BBQ90175891-4CD89351-925F-403B-ADA7-D43A1358E63BQ90304956-A50D2E20-56BC-43F1-9F0F-E133B954FE5AQ90334516-AB264781-0AAA-46A5-8624-F6D8E503384EQ90713647-D37D6255-E680-4B8A-9E12-136078CDBAACQ91129947-61518724-746E-4730-8180-5F70FA3D5080Q91310804-FC78D165-4EAB-4CB8-8235-E0B6FADF1D8DQ91830693-B61D6314-1A0A-4159-ACC9-B26F02CF60BFQ92864374-49AD6899-E54B-43EB-978E-815FC08168E0Q93271524-E5F1C13A-4C8C-4C6A-A85D-F36C0EAE00B2
P50
description
researcher
@en
name
Andrea Chiricozzi
@en
type
label
Andrea Chiricozzi
@en
prefLabel
Andrea Chiricozzi
@en
P31
P496
0000-0002-6739-0387